Myocardial fibrosis and pro-fibrotic markers in end-stage heart failure patients during continuous-flow left ventricular assist device support

European Journal of Cardio-thoracic Surgery

Volumn 48, Issue 3, 2015, Pages 407-415

  Lok, Sjoukje I ^a   Nous, Fay M A ^a   van Kuik, Joyce ^a   van der Weide, Petra ^a   Winkens, Bjorn ^b   Kemperman, Hans ^a   Huisman, Andre ^a   Lahpor, Jaap R ^a   de Weger, Roel A ^a   de Jonge, Nicolaas ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Biomarkers; Fibrosis; Heart failure; LVAD; Reverse remodelling

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CONNECTIVE TISSUE GROWTH FACTOR; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GALECTIN 3; INOTROPIC AGENT; MESSENGER RNA; OSTEOPONTIN; TRANSFORMING GROWTH FACTOR BETA1; BIOLOGICAL MARKER; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CELL SIZE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MALE; PACEMAKER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STROMA CELL; ADVERSE EFFECTS; BLOOD; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; COMPLICATION; CYTOLOGY; FIBROSIS; HEART ASSIST DEVICE; HEART VENTRICLE REMODELING; MIDDLE AGED; PATHOLOGY;

ADULT; BIOMARKERS; CONNECTIVE TISSUE GROWTH FACTOR; FEMALE; FIBROSIS; GALECTIN 3; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; OSTEOPONTIN; TRANSFORMING GROWTH FACTOR BETA; VENTRICULAR REMODELING;

EID: 84930897129     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezu539     Document Type: Article

References (25)

1. Birks EJ, Tansley PD, Hardy J, George RS, Bowles CT, Burke M et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006;355:1873-84.
2. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009;361:2241-51.
3. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MSV et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009;119:2408-16.
4. Saito S, Matsumiya G, Sakaguchi T, Miyagawa S, Yamauchi T, Kuratani T et al. Cardiac fibrosis and cellular hypertrophy decrease the degree of reverse remodeling and improvement in cardiac function during left ventricular assist. J Heart Lung Transplant 2010;29:672-9.
5. Ogawa Y, Tamura N, Chusho H, Nakao K. Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart. Can J Physiol Pharmacol 2001;79:723-9.
6. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 2001;23:291-9.
7. Drakos SG, Kfoury AG, Hammond EH, Reid BB, Revelo MP, Rasmusson BY et al. Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart. J Am Coll Cardiol 2010;56:382-91.
8. Lok SI, Winkens B, Goldschmeding R, van Geffen AJP, Nous FMA, van Kuik J et al. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail 2012;14:1249-56.
9. Maybaum S, Mancini D, Xydas S, Starling RC, Aaronson K, Pagani FD et al. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation 2007;115 (19):2497-505.
10. Kato TS, Chokshi A, Singh P, Khawaja T, Cheema F, Akashi H et al. Effects of continuous-flow versus pulsatile-flow left ventricular assist devices on myocardial unloading and remodeling. Circ Heart Fail 2011;4:546-53.
11. Barbone A, Holmes JW, Heerdt PM, The AH, Naka Y, Joshi N et al. Comparison of right and left ventricular responses to left ventricular assist device support in patients with severe heart failure: a primary role of mechanical unloading underlying reverse remodeling. Circulation 2001;104:670-5.
12. Matsumiya G, Monta O, Fukushima N, Sawa Y, Funatsu T, Toda K et al. Who would be a candidate for bridge to recovery during prolonged mechanical left ventricular support in idiopathic dilated cardiomyopathy? J Thorac Cardiovasc Surg 2005;130:699-704.
13. Ambardekar AV, Buttrick PM. Reverse remodeling with left ventricular assist devices: a review of clinical, cellular, and molecular effects. Circ Heart Fail 2011;4:224-33.
14. Pruijsten RV, Lok SI, Kirkels HH, Klöpping C, Lahpor JR, de Jonge N. Functional and haemodynamic recovery after implantation of continuousflow left ventricular assist devices in comparison with pulsatile left ventricular assist devices in patients with end-stage heart failure. Eur J Heart Fail 2012;14:319-25.
15. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JPM, Schroen B et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004;110:3121-8.
16. van Kimmenade RR, Januzzi JL, Ellinor PT, Sharma UC, Bakker JA, Low AF et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006;48:1217-24.
17. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RRJ, Januzzi JL. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010; 12:826-32.
18. Milting H, Ellinghaus P, Seewald M, Cakar H, Bohms B, Kassner A et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 2008;27:589-96.
19. Erkilet G, Özpeker C, Böthig D, Kramer F, Röfe D, Bohms B et al. The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices. J Heart Lung Transplant 2013;32: 221-30.
20. Daniels A, van Bilsen M, Goldschmeding R, van der Vusse GJ, van Nieuwenhoven FA. Connective tissue growth factor and cardiac fibrosis. Acta Physiol (Oxf ) 2009;195:321-38.
21. Urtasun R, Lopategi A, George J, Leung T-M, Lu Y, Wang X et al. Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin α(V)ß(3) engagement and PI3K/pAkt/NFκB signaling. Hepatology 2012;55:594-608.
22. Rosenberg M, Zugck C, Nelles M, Juenger C, Frank D, Remppis A et al. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail 2008;1:43-9.
23. Rosenberg M, Meyer FJ, Gruenig E, Lutz M, Lossnitzer D, Wipplinger R et al. Osteopontin predicts adverse right ventricular remodelling and dysfunction in pulmonary hypertension. Eur J Clin Invest 2012;42: 933-42.
24. Schipper MEI, Scheenstra MR, van Kuik J, van Wichen DF, van der Weide PDullens HFJ et al. Osteopontin: a potential biomarker for heart failure and reverse remodeling after left ventricular assist device support. J Heart Lung Transplant 2011;30:805-10.
25. Felkin LE, Lara-Pezzi E, George R, Yacoub MH, Birks EJ, Barton PJR. Expression of extracellular matrix genes during myocardial recovery from heart failure after left ventricular assist device support. J Heart Lung Transplant 2009;28:117-22.